Equities

Oxford Nanopore Technologies PLC

ONT:LSE

Oxford Nanopore Technologies PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)110.10
  • Today's Change3.70 / 3.48%
  • Shares traded1.72m
  • 1 Year change-51.67%
  • Beta--
Data delayed at least 20 minutes, as of May 03 2024 17:07 BST.
More ▼

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Oxford Nanopore Technologies PLC's revenues fell -14.57% from 198.60m to 169.67m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 91.03m to a larger loss of 154.51m.
Gross margin53.33%
Net profit margin-91.06%
Operating margin-99.29%
Return on assets-19.30%
Return on equity-23.11%
Return on investment-21.93%
More ▼

Cash flow in GBPView more

In 2023, cash reserves at Oxford Nanopore Technologies PLC fell by 136.24m. Cash Flow from Financing totalled 64.73m or 38.15% of revenues. In addition the company used 137.30m for operations while cash used for investing totalled 61.79m.
Cash flow per share-0.1354
Price/Cash flow per share--
Book value per share0.7493
Tangible book value per share0.711
More ▼

Balance sheet in GBPView more

Oxford Nanopore Technologies PLC appears to have a strong balance sheet with enough cash in the capital structure to pay down 100% of the liabilities.
Current ratio5.01
Quick ratio3.87
Total debt/total equity0.0647
Total debt/total capital0.0608
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.